University of Texas Medical Branch, Galveston: Scientists "have successfully engineered an anti-tau antibody that only targets tau oligomer aggregates of the protein. The antibody was powerful enough to reverse severe cognitive and motor symptoms in an alpha-synuclein animal model, they reported here on Tuesday at the Society for Neuroscience annual meeting.
"The researchers said the strategy could be used to treat Parkinson’s disease (PD) and Lewy body dementia (LBD), as well as other neurodegenerative conditions.
"[Rakez Kayed, PhD] and colleagues injected seven-month-old mice overexpressing the mutated alpha-synuclein with either a tau oligomer-specific antibody (TOMA), an antibody targeting all forms of tau, or a control (immunoglobulin G) antibody. Healthy (wild-type) mice were injected with saline. Two weeks later, they conducted a battery of tests assessing cognitive and motor function, and found that the severe phenotype (motor and cognitive deficits) were reversed in the mice that had received TOMA."
(nice to know the 'race for a cure' is alive and well ;P )
🧠 Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains
From S of PD. Could all the benefit of B1 be the placebo affect? I think it's time for me to switch to benfotiamine instead.
A fresh look at an old supp: Curcumin.
